Press release

Enodia Therapeutics acquires Sec61 preclinical assets from Kezar Life Sciences to expand its targeted protein degradation platform and accelerate development of small-molecule inhibitors.

Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning Seed round co-led by Elaia, Pfizer Ventures and Bpifrance Machine-learning platform enables signal peptide-informed...

Argobio and the Institut Pasteur launch Enodia Therapeutics: A biotech company with a new approach for Targeted protein Degradation Turning groundbreaking research from the Institut Pasteur with the support of Argobio's start-up studio, into novel treatments for...